



Expert Forum on MULTIPLE MYELOMA

AUG
23-24,
2019
DALLAS, TX



KEY OBJECTIVES

- Review the current genomic landscape of multiple myeloma, clinical features of poor prognosis, mechanisms of resistance, immune signatures, and the integration of MRD into clinical trials
- Examine the evolving role of transplantation and cellular therapy for the treatment of multiple myeloma, including CAR-T, ASCT, and allogeneic SCT
- Evaluate key aspects of supportive care and complications, including bone disease, as well as definitions of disease, especially SMM/MGUS
- Debate proteasome inhibitors, how to tailor treatment to patient populations, and broader strategies to overcome proteasome inhibitor resistance
- Consider the benefits and challenges of long term lenalidomide therapy, as well as the emerging role of next generation IMiDs and Cell Mods
- Discuss the integration of novel therapies and MoAbs in particular, including SLAMF7, CD 38, CAR-T cell therapy and targeting BCL2, as well as vaccines, and other novel targets, including nuclear export proteins and peptidase-avid alkylation
- Understand the continued potential of targeting BCMA both in the setting of CAR-T therapy and MoAbs/ADC's